SSE | Jotup

Banco Itaú Chile Announces Termination of American Depositary Shares Program

Retrieved on:

Donnerstag, November 9, 2023

NYSE, Deposit, American depositary receipt, ITCL, BNY Mellon, SSE, Bank, Depositary, Annex, Security (finance), Lease

SANTIAGO, Chile, Nov. 09, 2023 (GLOBE NEWSWIRE) -- BANCO ITAÚ CHILE (NYSE: ITCL; SSE: ITAUCL) (the “Company”) today announces that The Bank of New York Mellon, as depositary (the “Depositary”) issued, on November 8, 2023, a notice (the “Termination Notice”) to the holders of American Depositary Shares (the “ADSs”) representing common shares of the Company terminating the American Depository Receipt program (the “ADR Program”) according to the requirements under the Amended and Restated Deposit Agreement dated as of June 11, 2018 (the “Deposit Agreement”) among the Company, the Depositary, and owners and holders from time to time of ADSs issued thereunder.

Key Points:

SANTIAGO, Chile, Nov. 09, 2023 (GLOBE NEWSWIRE) -- BANCO ITAÚ CHILE (NYSE: ITCL; SSE: ITAUCL) (the “Company”) today announces that The Bank of New York Mellon, as depositary (the “Depositary”) issued, on November 8, 2023, a notice (the “Termination Notice”) to the holders of American Depositary Shares (the “ADSs”) representing common shares of the Company terminating the American Depository Receipt program (the “ADR Program”) according to the requirements under the Amended and Restated Deposit Agreement dated as of June 11, 2018 (the “Deposit Agreement”) among the Company, the Depositary, and owners and holders from time to time of ADSs issued thereunder.
The ADR Program and the Deposit Agreement will be terminated on February 5, 2024 (the “Termination Date”).
The Termination Notice, a copy of which is included as an Annex to this press release, describes instructions to be followed by holders of ADSs in connection with the termination of the ADR Program and of the Deposit Agreement.

InnoCare Appoints Xin Fu as Chief Financial Officer

Retrieved on:

Montag, Dezember 18, 2023

Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, HKEX, Therapy, CFO, CMA, Strategic planning, SSE, IPO, Financial management, Cancer, Hong Kong Stock Exchange, Fudan University, Management

InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, announced today that the Company appointed Mr. Xin Fu, who has extensive finance-related experience, as the Chief Financial Officer (CFO).

Key Points:

InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, announced today that the Company appointed Mr. Xin Fu, who has extensive finance-related experience, as the Chief Financial Officer (CFO).
Mr. Fu has over 20 years of financial management experience, including 15 years in the healthcare industry.
Before joining InnoCare, Mr. Fu served as the Chief Financial Officer at JW Therapeutics, where he played a critical role in the completion the of IPO in the Hong Kong Stock Exchange, company strategy planning, investment and financing activities, etc.
Prior to JW Therapeutics, Mr. Fu held multiple leadership positions at Pfizer China, including Chief Financial Officer and Chief Compliance Officer.

InnoCare Announces Phase II Study Results of TYK2 Inhibitor ICP-332 Meet Primary Endpoint in Patients with Atomic Dermatitis

Retrieved on:

Sonntag, Dezember 17, 2023

Biotechnology, Pharmaceutical, Health, Clinical Trials, HKEX, SSE, Trial of the century, Patient, TYK2, Cancer, IGA, EASI

InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that phase II clinical study results of novel TYK2 (Tyrosine Kinase 2) inhibitor ICP-332 met primary endpoint in adult patients with moderate-to-severe atopic dermatitis (AD).

Key Points:

InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that phase II clinical study results of novel TYK2 (Tyrosine Kinase 2) inhibitor ICP-332 met primary endpoint in adult patients with moderate-to-severe atopic dermatitis (AD).
We will further accelerate the clinical development to benefit patients with AD and other autoimmune diseases.”
By now, there is no TYK2 inhibitor approved for the AD globally.
The study is a randomized, double-blind, placebo-controlled phase II clinical trial to evaluate the safety, efficacy, pharmacokinetics and pharmacodynamics of ICP-332 in patients with moderate-to-severe atopic dermatitis.
ICP-332 is a potent and selective TYK-2 inhibitor with about 400 folds of selectivity against JAK2 to avoid the adverse events associated with non-selective JAK inhibitors.

Hillstone Networks Included in Security Service Edge Solutions Landscape Report

Retrieved on:

Dienstag, Dezember 12, 2023

Data Management, Security, Technology, Mobile, Wireless, Software, Networks, Internet, Security Service, SSE, ZTNA, Organization, Jane Hillston, Network, Online shopping

Hillstone Networks , a leading provider of cybersecurity solutions, is included in the Security Service Edge Solutions Landscape Report for Q4 2023.

Key Points:

Hillstone Networks , a leading provider of cybersecurity solutions, is included in the Security Service Edge Solutions Landscape Report for Q4 2023.
The Forrester Report offers an overview of the market landscape for Security Service Edge (SSE) solutions, which are deployed to provide Zero Trust access to apps and data and to secure a remote workforce.
“SSE solutions address a real problem in gaps in security in an increasingly expanding network edge,” states Tim Liu, CTO and Co-founder at Hillstone Networks.
To meet these hybrid, any device, anywhere access challenges, Hillstone’s Edge solutions suite includes zero-trust network access (ZTNA) technology.

Latest Data of InnoCare’s Oncology Pipelines Presented at the 65th Annual Meeting of ASH

Retrieved on:

Montag, Dezember 11, 2023

InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the latest data from InnoCare’s oncology studies were presented at the 65th American Society of Hematology (ASH) Annual Meeting.

Key Points:

InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the latest data from InnoCare’s oncology studies were presented at the 65th American Society of Hematology (ASH) Annual Meeting.
The study of orelabrutinib’s regimen in patients with untreated mantle cell lymphoma (MCL) was selected as an oral presentation.
The overall response rate (ORR) was 100%, and the complete response rate (CRR) was 76.2%.
This retrospective data suggests that orelabrutinib in combination with rituximab has an encouraging anti-tumor activity in MZL, with a favorable safety profile.

ICE Awarded $155 Million For PennyMac Misuse of Black Knight Confidential Information in Mortgage Servicing Software

Retrieved on:

Dienstag, Dezember 5, 2023

Professional Services, Data Management, Other Professional Services, Technology, Other Technology, Software, Finance, PennyMac Financial Services, Intercontinental, SSE, Acquisition, NYSE, Black Knight, Intercontinental Exchange, ICE

Intercontinental Exchange, Inc. (NYSE: ICE) is a Fortune 500 company that designs, builds, and operates digital networks that connect people to opportunity. We provide financial technology and data services across major asset classes helping our customers access mission-critical workflow tools that increase transparency and efficiency. ICE’s futures, equity, and options exchanges -- including the New York Stock Exchange -- and clearing houses help people invest, raise capital and manage risk. We offer some of the world’s largest markets to trade and clear energy and environmental products. Our fixed income, data services and execution capabilities provide information, analytics and platforms that help our customers streamline processes and capitalize on opportunities. At ICE Mortgage Technology, we are transforming U.S. housing finance, from initial consumer engagement through loan production, closing, registration and the long-term servicing relationship. Together, ICE transforms, streamlines, and automates industries to connect our customers to opportunity.

Key Points:

The arbitrator awarded more than $155 million dollars, plus interest and attorneys’ fees to Black Knight based on PennyMac’s conduct.
PennyMac is a former client of Black Knight, and ICE completed its acquisition of Black Knight in September 2023.
The arbitrator determined that in developing its SSE software, PennyMac incorporated confidential information from Black Knight’s MSP system and breached its contract with Black Knight with respect to such confidential information.
ICE will continue to seek the robust protections afforded to trade secrets and confidential information under federal and state law, including in products developed using its confidential information.

CSOP Huatai-PineBridge SSE Dividend Index ETF to be Listed on SGX Today

Retrieved on:

Freitag, Dezember 1, 2023

Asset Management, Professional Services, Finance, ETF, CSOP, Multimedia, YTD, RMB, SSE, Memorandum of understanding, SGD, SGX, Singapore Exchange, QFI, China Southern Asset Management, AUM, Shanghai Stock Exchange, Holding company, Security (finance)

CSOP Huatai-PineBridge SSE Dividend Index ETF (Stock Code: SHD) lists on 1 December 2023 on Singapore Exchange (SGX Group).

Key Points:

CSOP Huatai-PineBridge SSE Dividend Index ETF (Stock Code: SHD) lists on 1 December 2023 on Singapore Exchange (SGX Group).
SHD is a feeder fund, which will invest at least 90% of its Net Asset Value in the Huatai-PineBridge SSE Dividend Index ETF, referred to as the “Underlying Fund”.
The SSE Dividend Index comprises of 50 high quality dividend-paying companies listed on the Shanghai Stock Exchange (SSE) as its constituents.
The CSOP Huatai-PineBridge SSE Dividend Index ETF is one of the first pair of products under the SSE-SGX ETF link, providing Singapore investors with access to high-quality A-share opportunities.

BeiGene to Host ASH Investor Meeting in Person and via Webcast on December 10, 2023

Retrieved on:

Mittwoch, November 29, 2023

Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Webcast, BeiGene, SSE, Society, BGNE, ASH, Cryptocurrency, Online shopping

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced that it will host an Investor Event at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego and via webcast at 8:00 PM PST on December 10, 2023.

Key Points:

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced that it will host an Investor Event at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego and via webcast at 8:00 PM PST on December 10, 2023.
This event will cover BeiGene’s R&D progress and broad hematology portfolio, with invited speakers presenting key data from the ASH 2023.
A live webcast of this event can be accessed from the investors section of BeiGene’s website at http://ir.beigene.com , https://hkexir.beigene.com/ , https://sseir.beigene.com/ .
Archived replays will be available for 90 days following the event.

BeiGene to Present New Data Highlighting Hematology Portfolio and Pipeline Strengths at ASH 2023

Retrieved on:

Dienstag, November 28, 2023

BeiGene has 24 abstracts accepted at ASH, with three abstracts scheduled for oral presentations.

Key Points:

BeiGene has 24 abstracts accepted at ASH, with three abstracts scheduled for oral presentations.
“Our data at ASH showcase BeiGene’s leadership in the treatment of blood cancers, with promising clinical advances across our pipeline.
BeiGene will host an event in San Diego on Sunday, December 10 at 8:00 pm PST for investors and analysts attending ASH.
BeiGene senior management and invited speakers will review BeiGene’s pipeline and highlights of the presented data, followed by a Q&A panel.

BeiGene and Ensem Therapeutics Announce Partnership to Advance Differentiated CDK2 Inhibitor

Retrieved on:

Dienstag, November 21, 2023

Biotechnology, Pharmaceutical, Health, Oncology, Kinetic, BGNE, Breast cancer, CDK4, Patient, Doctor of Philosophy, SSE, Drug discovery, Cancer, Partnership, CDK2, Pharmaceutical industry, BeiGene, IND

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, and Ensem Therapeutics, Inc. (ENSEM), a biotechnology company focusing on high-value and difficult-to-drug oncology targets, today announced an agreement for BeiGene to acquire an exclusive global license to an Investigational New Drug (IND) application-ready oral cyclin-dependent kinase 2 (CDK2) inhibitor.

Key Points:

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, and Ensem Therapeutics, Inc. (ENSEM), a biotechnology company focusing on high-value and difficult-to-drug oncology targets, today announced an agreement for BeiGene to acquire an exclusive global license to an Investigational New Drug (IND) application-ready oral cyclin-dependent kinase 2 (CDK2) inhibitor.
“This CDK2 inhibitor from ENSEM complements our internally discovered Phase 1 CDK4 inhibitor, which has the potential to improve upon current CDK4/6 inhibitors in some breast cancer patients, and strengthens our early development pipeline in breast cancer and other solid tumors.
“We are pleased to partner with BeiGene on the development of this differentiated CDK2 inhibitor,” said Shengfang Jin, Ph.D., President and Chief Executive Officer at ENSEM.
“We believe BeiGene is the right partner to advance our first IND-ready asset due to their wealth of expertise in bringing innovative cancer therapies to patients globally.